NFKB1 and Hepatic fibrosis: Combined results in the group treated with BTZ loaded in targeted NPs with VA, indicated a tremendous anti-fibrotic capacity by suppressing HSCs activation and reducing the expression of NF-κB and TGF-β, further ameliorating liver fibrosis in the CCL4-induced mouse model.